SMAD4

Across TCGA pan-cancer cohorts, SMAD4 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated SMAD4 data layer compared with 6 for mutation status and 3 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher SMAD4 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMAD4 expression acts as an unfavorable survival marker, although some lineages such as KIRC and PAAD show a favorable association.

ACC, KIRC, and PAAD are the cancer types where SMAD4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.191	0.692	<.001	98	view →
KIRC	OS	Tertile	All	0.781	0.592	<.001	74	view →
PAAD	DFS	Tertile	All	0.411	0.141	.002	37	view →
GBM	DFS	Median	All	0.423	0.168	<.001	18	view →
THYM	DFS	Tertile	II,III,IV	0.898	0.595	.009	17	view →
PRAD	DFS	Quartile	All	0.975	0.857	<.001	16	view →
MESO	DFS	Tertile	IV	0.320	0.760	.021	15	view →
UVM	OS	Quartile	III,IV	0.214	0.809	.012	12	view →
LIHC	OS	Quartile	II,III,IV	0.434	0.797	.001	12	view →
CHOL	DFS	Median	All	0.745	0.139	.010	9	view →
COAD	OS	Median	IV	0.785	0.499	.013	8	view →
THCA	OS	Tertile	II,III,IV	0.675	0.875	.009	7	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

SMAD4–ACC (DFS)

Open the ACC breakdown →